A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study

Grigoris T Gerotziafas 1 2, Ali Taher 3, Hikmat Abdel-Razeq 4, Essam AboElnazar 5, Alex C Spyropoulos 6, Salem El Shemmari 7, Annette K Larsen 8, Ismail Elalamy 8 2; COMPASS–CAT Working Group

Affiliations

01 October 2017

-

doi: 10.1634/theoncologist.2016-0414

Abstract

Background: The stratification of outpatients on chemotherapy for breast, colorectal, lung, and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical need. The derivation of a risk assessment model (RAM) for VTE in these patients was the aim of the study "Prospective Comparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real life patients-Cancer Associated Thrombosis" (COMPASS-CAT).

Patients and methods: The derivation cohort consisted of 1,023 outpatients. Patients on low molecular weight heparin (LMWH) thromboprophylaxis were excluded. Documented symptomatic VTE was the endpoint of the study.

Results: Patients had breast (61%), colorectal (17%), lung (13%), or ovarian cancer (8.6%) at localized (30%) or advanced stage (70%). In 64% of patients, cancer was diagnosed within the last 6 months prior to inclusion. Most of them were on chemotherapy when assessed. Symptomatic VTE occurred in 8.5% of patients. The COMPASS-CAT RAM includes the following variables: (a) anthracycline or anti-hormonal therapy, (b) time since cancer diagnosis, (c) central venous catheter, (d) stage of cancer, (e) presence of cardiovascular risk factors, (f) recent hospitalization for acute medical illness, (g) personal history of VTE, and (h) platelet count. At 6 months, patients stratified at low/intermediate and high-risk groups had VTE rates of 1.7% and 13.3%, respectively. The area under the curve of receiver operating characteristics analysis was 0.85. The sensitivity and specificity of the RAM were 88% and 52%, respectively. The negative and positive predictive values of the RAM were 98% and 13%, respectively.

Conclusion: The COMPASS-CAT RAM includes reliable and easily collected VTE risk predictors and, in contrast to the Khorana score, it is applicable after the initiation of anticancer treatment in patients with common solid tumors. Its robustness for stratification of patients at high and low/intermediate VTE risk needs to be externally validated.

Implications for practice: The Prospective Comparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real life patients-Cancer Associated Thrombosis (COMPASS-CAT) study provides a new risk assessment model (RAM) for venous thromboembolism (VTE) applicable in outpatients with breast, colorectal, lung or ovarian cancer. The COMPASS-CAT RAM is robust, applicable during chemotherapy and determines the need for VTE prévention by including reliable and easily collected VTE predictors associated with cancer status, its treatment as well as with patients' characteristics and comorbidities. An independent external validation of the RAM is indicated before its use in clinical practice.

Keywords: Breast cancer; Cancer‐associated thrombosis; Colon cancer; Lung cancer; Ovarian cancer; Risk assessment model.

Similar articles

External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.

Spyropoulos AC, Eldredge JB, Anand LN, Zhang M, Qiu M, Nourabadi S, Rosenberg DJ.Oncologist. 2020 Jul;25(7):e1083-e1090. doi: 10.1634/theoncologist.2019-0482. Epub 2020 Feb 4.PMID: 32017293 Free PMC article.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13.PMID: 30104289 Free PMC article.

Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.

Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H.Med Oncol. 2018 Apr 3;35(5):63. doi: 10.1007/s12032-018-1120-9.PMID: 29616356 Free PMC article.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156.PMID: 25485915 Review.

Derivation and External Validation of a Risk Assessment Model of Venous Thromboembolism in Hospitalized Chinese Patients.

Chen X, Huang J, Liu J, Chang J, Pan L, Wang Y, Gao Y, Yang Y.Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296221151164. doi: 10.1177/10760296221151164.PMID: 36650933 Free PMC article. Review.


 

Cited by

Cited by

Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges.

Olivi M, Di Biase F, Lanzarone G, Arrigo G, Martella F, Apolito V, Secreto C, Freilone R, Bruno B, Audisio E, Ferrero D, Beggiato E, Cerrano M.Curr Treat Options Oncol. 2023 Apr 26. doi: 10.1007/s11864-023-01089-w. Online ahead of print.PMID: 37099265 Review.

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.

Xiong W, Guo X, Du H, Xu M, Zhao Y.BMJ Open Respir Res. 2023 Apr;10(1):e001493. doi: 10.1136/bmjresp-2022-001493.PMID: 37068846 Free PMC article. Review.

Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients.

Lan Y, Wu L, Guo J, Wang J, Guan H, Li B, Liu L, Zhang L, Hong Y, Deng J, Zhu J, Lu S, Sun F, Huang J, Sun X, Zhang Y, Wang J, Cai R.Sci Rep. 2023 Mar 2;13(1):3553. doi: 10.1038/s41598-023-30763-0.PMID: 36864082 Free PMC article.

The burden and predictors of venous thromboembolic diseases in patients with multiple primary malignancies.

Alhamadh MS, Alanazi RB, Alqirnas MQ, Alhabeeb AY, Chachar YS, Alkaiyat M, Sabatin F.Cancer Rep (Hoboken). 2023 Mar;6(3):e1742. doi: 10.1002/cnr2.1742. Epub 2022 Oct 31.PMID: 36314077 Free PMC article.

A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score.

Norris LA, Ward MP, O'Toole SA, Marchocki Z, Ibrahim N, Khashan AS, Abu Saadeh F, Gleeson N.Res Pract Thromb Haemost. 2020 May 28;4(5):848-859. doi: 10.1002/rth2.12342. eCollection 2020 Jul.PMID: 32685894 Free PMC article.


 

References

  1.  
    1. Lyman GH, Khorana AA, Falanga A. Thrombosis and cancer: Emerging data for the practicing oncologist. Am Soc Clin Oncol Educ Book, 2013. - PubMed
  2.  
    1. Gary T, Belaj K, Steidl K et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: Impact on short‐term survival. Br J Cancer 2012;107:1244–1248. - PMC - PubMed
  3.  
    1. Chew HK, Wun T, Harvey DJ et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70–76. - PubMed
  4.  
    1. Walker AJ, West J, Card TR et al. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood 2016;127:849–857. - PMC - PubMed
  5.  
    1. Ahern TP, Horváth‐Puhó E, Spindler KG et al. Colorectal cancer, comorbidity, and risk of venous thromboembolism: Assessment of biological interactions in a Danish nationwide cohort. Br J Cancer 2016;114:96–102. - PMC - PubMed
  6.  
    1. Salla E, Dimakakos EP, Tsagkouli S et al. Venous thromboembolism in patients diagnosed with lung cancer. Angiology 2016;67:709–724. - PubMed
  7.  
    1. Chen EC, Papa N, Lawrentschuk N et al. Incidence and risk factors of venous thromboembolism after pelvic uro‐oncologic surgery—A single center experience. BJU Int 2016;117(suppl 4):50–53. - PubMed
  8.  
    1. Tran BH, Nguyen TJ, Hwang BH et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast 2013;22:444–448. - PubMed
  9.  
    1. Moore RA, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin‐based chemotherapy: A large retrospective analysis. J Clin Oncol 2011;29:3466–3473. - PMC - PubMed
  10.  
    1. Wun T, White RH. Epidemiology of cancer‐related venous thromboembolism. Best Pract Res Clin Haematol 2009;22:9–23. - PMC - PubMed
  11.  
    1. Akl EA, Kahale LA, Ballout RA et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev: 2014:CD006652. - PubMed
  12.  
    1. Kahn SR, Lim W, Dunn AS et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest 2012;141(suppl 2):e195S–e226S. - PMC - PubMed
  13.  
    1. Nicolaides AN, Fareed J, Kakkar AK et al. Prevention and treatment of venous thromboembolism—International Consensus Statement. Int Angiol 2013;32:111–260. - PubMed
  14.  
    1. Debourdeau P, Farge D, Beckers M et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013;11:71–80. - PubMed
  15.  
    1. Di Nisio M, Porreca E, Otten HM et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev: 2014:CD008500. - PubMed
  16.  
    1. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015. 20;33:654–656. - PMC - PubMed
  17.  
    1. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy‐associated thrombosis. Blood 2008;111:4902–4907. - PMC - PubMed
  18.  
    1. Verso M, Agnelli G, Barni S et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score. Intern Emerg Med 2012;7:291–292. - PubMed
  19.  
    1. Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377–5382. - PubMed
  20.  
    1. Agnelli G, George DJ, Kakkar AK et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601–609. - PubMed
  21.  
    1. George D, Agnelli G, Fisher W et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: Benefit‐risk assessment by VTE risk in SAVE‐ONCO. Paper presented at: American Society of Hematology 53rd Annual meeting; December 10–13, 2011; San Diego, California.
  22.  
    1. Mansfield A, Tafur AJ, Wang CE et al. Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer. J Thromb Haemost 2016;14:1773–1778. - PMC - PubMed
  23.  
    1. Alikhan R, Cohen AT, Combe S et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study. Arch Intern Med 2004;164:963–968. - PubMed
  24.  
    1. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001;38:12–19. - PubMed
  25.  
    1. Mokhtari M, Salameh P, Kouchek M et al. The AVAIL ME Extension: A multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. J Thromb Haemost 2011;9:1340–1349. - PubMed
  26.  
    1. Hendriksen JM, Geersing GJ, Moons KG et al. Diagnostic and prognostic prediction models. J Thromb Haemost 2013;11(suppl 1):129–141. - PubMed
  27.  
    1. Harrell FE Jr, Lee KL, Mark DB et al. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387. - PubMed
  28.  
    1. Peduzzi P, Concato J, Kemper E et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–1379. - PubMed
  29.  
    1. Wasson JH, Sox HC, Neff RK et al. Clinical prediction rules: Applications and methodological standards. N Engl J Med 1985;313:793–799. - PubMed
  30.  
    1. Ashrani AA, Gullerud RE, Petterson TM et al. Risk factors for incident venous thromboembolism in active cancer patients: A population based case‐control study. Thromb Res 2016;139:29–37. - PMC - PubMed
  31.  
    1. Parienti JJ, Mongardon N, Mégarbane B et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med 2015;373:1220–1229. - PubMed
  32.  
    1. Sevestre MA, Belizna C, Durant C et al. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study. J Mal Vasc 2014;39:161–168. - PubMed
  33.  
    1. Aggarwal A, Fullam L, Brownstein AP et al. Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer. Cancer Invest 2015;33:405–410. - PubMed
  34.  
    1. Dentali F, Pegoraro S, Barco S et al. Clinical history of cancer patients with isolated distal deep vein thrombosis: A multicenter cohort study. Thromb Res 2016;(140 suppl 1):S168 - PubMed
  35.  
    1. Ho P, Lim HY, Chua CC et al. Retrospective review on isolated distal deep vein thrombosis (IDDVT) ‐ A benign entity or not? Thromb Res 2016;142:11–16. - PubMed
  36.  
    1. Sartori M, Migliaccio L, Favaretto E et al. Two years outcome of isolated distal deep vein thrombosis. Thromb Res 2014;134:36–40. - PubMed

Page Navigation